This week, the European Parliament’s Health Committee introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers.
This week, the European Parliament’s Health Committee (ENVI) introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The SPC is meant to offset the loss of patent protection that takes place during the development of a generic or biosimilar.
In May, the European Commission (EC) proposed revising SPCs in order to boost the development and manufacturing of biosimilars and generics. The proposal looked to introduce a manufacturing exemption for export purposes during the term of an SPC. The exemption would restrict the protection allowed by the SPC in order to remove competitive disadvantages to EU-based generic and biosimilar developers by allowing a drug maker to manufacture a product in an EU member state for the sole purpose of exporting a product to a non-EU market that is not subject to an SPC.
The current waiver also blocks the production and stockpiling of generics and biosimilars to allow for “day 1” launches after SPC expiry. Due to such restrictions, the EU pharmaceutical industry instead must delocalize production to non-EU countries such as Canada, India, China, and the United States.
In its most recently submitted amendments, ENVI “sent a clear signal of support with the adoption of a ‘day 1’ launch possibility to supply European patients with European manufactured medicines.” As the EU expects €90 billion (approximately $102 billion) worth of blockbuster medicines coming off patent in 2020, this amendment could have significant implications for industry.
ENVI additionally noted the need to protect trade secrets and commercially confidential information in the context of a procedure to notify other manufacturers of patent expiry. However, the committee also “maintained the very long lead time for implementing the waiver which will delay its ability to create manufacturing and access opportunities for many years.”
Adrian van den Hoven, director general of Medicines for Europe, commented in a statement, “We hope that this progress, together with a more reasonable date of application, will be agreed by the Parliament and the Council in a future final agreement. We urge the Parliament’s Legal Committee to adopt a final opinion that includes these important priorities for health, for jobs, and for a robust pharmaceutical ecosystem.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.